Introduction: As the United States population ages, the adult population with chronic diseases is expected to increase. Exploring credible, evidence-based projections of the future burden of chronic diseases is fundamental to understanding the likely impact of established and emerging interventions on the incidence and prevalence of chronic disease. Projections of chronic disease often involve cross-sectional data that fails to account for the transition of individuals across different health states. Thus, this research aims to address this gap by projecting the number of adult Americans with chronic disease based on empirically estimated age, gender, and race-specific transition rates across predetermined health states.
Methods: We developed a multi-state population model that disaggregates the adult population in the United States into three health states, i.e., (a) healthy, (b) one chronic condition, and (c) multimorbidity. Data from the 1998 to 2018 Health and Retirement Study was used to estimate age, gender, and race-specific transition rates across the three health states, as input to the multi-state population model to project future chronic disease burden.
Results: The number of people in the United States aged 50 years and older will increase by 61.11% from 137.25 million in 2020 to 221.13 million in 2050. Of the population 50 years and older, the number with at least one chronic disease is estimated to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. At the same time, those with multimorbidity are projected to increase 91.16% from 7.8304 million in 2020 to 14.968 million in 2050. By race by 2050, 64.6% of non-Hispanic whites will likely have one or more chronic conditions, while for non-Hispanic black, 61.47%, and Hispanic and other races 64.5%.
Conclusion: The evidence-based projections provide the foundation for policymakers to explore the impact of interventions on targeted population groups and plan for the health workforce required to provide adequate care for current and future individuals with chronic diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881650 | PMC |
| http://dx.doi.org/10.3389/fpubh.2022.1082183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the relationship between periodontal diseases and osteoporosis: Potential role of butyrate.
Biomed Pharmacother
December 2024
College of Dental Medicine, Lincoln Memorial University, LMU Tower, 1705 St. Mary Street, Knoxville, TN 37917, USA. Electronic address:
Osteoporosis, a condition marked by the loss of bone density and mass, affects individuals of all ages. However, it becomes more prevalent and severe with aging, increasing the risk of fractures and other health complications. Recent research has highlighted a link between osteoporosis and periodontitis, a chronic gum disease, as both conditions involve excessive bone loss that can lead to significant oral health problems if untreated.
View Article and Find Full Text PDFAssessment of Emphysema on X-ray Equivalent Dose Photon-Counting Detector CT: Evaluation of Visual Scoring and Automated Quantification Algorithms.
Invest Radiol
October 2024
From the Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland (B.K., F.E., J.K., T.F., L.J.); Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy (C.S., A.R.L.); and Section of Radiology, Department of Radiological and Hematological Sciences, Università Cattolica del Sacro Cuore, Rome, Italy (A.R.L.).
Objectives: The aim of this study was to evaluate the feasibility and efficacy of visual scoring, low-attenuation volume (LAV), and deep learning methods for estimating emphysema extent in x-ray dose photon-counting detector computed tomography (PCD-CT), aiming to explore future dose reduction potentials.
Methods: One hundred one prospectively enrolled patients underwent noncontrast low- and chest x-ray dose CT scans in the same study using PCD-CT. Overall image quality, sharpness, and noise, as well as visual emphysema pattern (no, trace, mild, moderate, confluent, and advanced destructive emphysema; as defined by the Fleischner Society), were independently assessed by 2 experienced radiologists for low- and x-ray dose images, followed by an expert consensus read.
Case control study of access to medications during COVID-19 and longitudinal impact on health outcomes for primary care patients managing multiple chronic conditions.
Fam Pract
December 2024
Department of Medicine, Larner College of Medicine, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405, United States.
Background: During coronavirus disease 2019 (COVID-19), people managing multiple chronic conditions (MCCs) experienced barriers to obtaining needed medications. The purposes of this paper are to (i) determine risk factors for difficulty obtaining medications during COVID-19, (ii) document reasons for the difficulty, and (iii) evaluate the impact on later physical and mental health outcomes.
Method: In a randomized controlled trial conducted in 2016-2021, 1969 adult primary care patients were surveyed about physical and mental health both before and during COVID-19.
Background: Dyspnoea is one of the emergency department's (ED) most common and deadly chief complaints, but frequently misdiagnosed and mistreated. We aimed to design a diagnostic decision support which classifies dyspnoeic ED visits into acute heart failure (AHF), exacerbation of chronic obstructive pulmonary disease (eCOPD), pneumonia and "other diagnoses" by using deep learning and complete, unselected data from an entire regional health care system.
Methods: In this cross-sectional study, we included all dyspnoeic ED visits of patients ≥ 18 years of age at the two EDs in the region of Halland, Sweden, 07/01/2017-12/31/2019.
[A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps].
Vestn Otorinolaringol
December 2024
St. Petersburg Research Institute of Ear, Throat, Nose and Speech, St. Petersburg, Russia.
Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!